BioCardia Reports Q2 2026 Earnings with Reduced Losses
BioCardia (BCDA) released its second-quarter earnings report for 2026, showing a net loss of $1.6 million compared to $2 million in the same period last year. The reduction was primarily due to lower research and development expenses following the closeout of the CardiAMP heart failure trial. As of June 30, 2026, BioCardia held cash and equivalents totaling $4.1 million, up from $2.5 million at the end of 2025. The company raised an additional $4.9 million through its at-the-market facility in Q2, with a stock price averaging $1.22 per share. BioCardia also highlighted progress on clinical trials and market expansion plans for Japan, where it aims to target up to 300,000 patients suffering from ischemic heart failure using the CardiAMP cell therapy system.
